IP Library Granted Patent US 8,337,553
Granted Patent B2
US 8,337,553 · App. 12/846,950 · Granted Dec 25, 2012

Optical material and method for modifying the refractive index

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,337,553
App. No.
12/846,950
Granted
Dec 25, 2012
Kind
B2
Abstract

The invention is directed to an optical device comprising refractive optical structures, wherein the refractive structures are characterized by a change in refractive index, exhibit little or no scattering loss, and exhibit no significant differences in the Raman spectrum with respect to the non-irradiated optical, polymeric material.

Claims (19)

1. An optical device comprising an optical polymeric material with select regions that have been irradiated with a focused, visible or near-IR laser having a pulse energy from 0.05 nJ to 1000 nJ, wherein the irradiated regions are characterized by a positive change in refractive index, exhibit little or no scattering loss, and exhibit no significant differences in the Raman spectrum with respect to the non-irradiated optical, polymeric material, wherein the optical polymeric material is a hydrogel.

2. The optical device of claim 1 wherein the irradiated regions of the optical material are defined by a three dimensional structure.

3. The optical device of claim 1 selected from an intraocular lens, a corneal inlay, a corneal ring or a keratoprothesis.

4. The optical device of claim 1 wherein the optical polymeric material is prepared from (meth)acrylate monomer selected from the group consisting of 2-hydroxymethyl(meth)acrylate, 2-phenylethyl(meth)acrylate, methyl(meth)acrylate and 3-phenylpropyl(meth)acrylate.

5. The optical device of claim 1 wherein the pulse energy of the laser is from 0.2 nJ to 100 nJ.

6. The optical device of claim 1 wherein the pulse energy of the laser is from 0.5 nJ to 10 nJ.

7. The optical device of claim 1 wherein the visible or near-IR laser generates pulses having a pulse width of 4 fs to 100 fs.

8. The optical device of claim 1 is an intraocular lens that has been positioned in the lens capsule of a patient.

9. The optical device of claim 1 wherein the optical, polymeric hydrogel is a copolymer that is prepared from a first monomeric component present in the copolymer in an amount of at least 70% by weight, and its homopolymer will have a refractive index of at least 1.50; a second monomeric component present in the copolymer in an amount from 3% to 20% by weight, and its homopolymer will have a glass transition temperature of less than about 300° C., wherein the first and second monomeric components together represent at least 80% by weight of the copolymer; and a crosslinking monomeric component.

10. The optical device of claim 9 wherein the copolymer is prepared in the presence of a fourth monomeric component, which is a hydrophilic component.

11. The optical device of claim 1 wherein the copolymer is prepared from a monomer having the formula:

wherein: R is H or CH 3 ; m is 0-10;

Y is nothing, 0, S, or NR wherein R is H, CH 3 , C n H 2n+1 (n=1-10), iso OC 3 H 7 , phenyl or benzyl;

Ar is any aromatic ring, such as benzene, which can be unsubstituted or substituted with H, CH 3 , C 2 H 5 , n-C 3 H 7 , iso-C 3 H 7 , OCH 3 , C 6 H 11 , Cl, Br, phenyl or benzyl; and

a cross-linking monomer having a plurality of polymerizable ethylenically unsaturated groups, wherein the resulting optical, polymeric material will have a glass transition temperature not greater than 37° C. and an elongation of at least 150%.

12. The optical device of claim 1 wherein the copolymer is prepared from about 80 wt % HEMA and about 20 wt % MMA with a water content of about 26%.

13. An optical device comprising an optical polymeric hydrogel material with select regions that have been irradiated with a focused, visible or near-IR laser having a pulse energy from 0.05 nJ to 100 nJ, wherein the irradiated regions are characterized by a positive change in refractive index, exhibit little or no scattering loss, and exhibit no significant differences in the Raman spectrum with respect to the non-irradiated optical, polymeric material, said optical, polymeric hydrogel is a copolymer that is prepared from a first monomeric component present in the copolymer in an amount of at least 70% by weight, and its homopolymer will have a refractive index of at least 1.50; a second monomeric component present in the copolymer in an amount from 3% to 20% by weight, and its homopolymer will have a glass transition temperature of less than about 300° C., wherein the first and second monomeric components together represent at least 80% by weight of the copolymer; and a crosslinking monomeric component.

14. The optical device of claim 13 wherein the copolymer is prepared in the presence of a fourth monomeric component, which is a hydrophilic component.

15. The optical device of claim 13 wherein the first monomeric components is selected from the group consisting of 2-phenylethyl(meth)acrylate and 3-phenylpropyl(meth)acrylate.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Feb 5, 2019
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 048259/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2015
From: KNOX, WAYNE H.; DING, LI
To: UNIVERSITY OF ROCHESTER
Reel/Frame 035695/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2015
From: KUNZLER, JAY F.; JANI, DHARMENDRA; PINTO, CANDIDO D.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 035695/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2015
From: KNOX, WAYNE; DING, LI
To: UNIVERSITY OF ROCHESTER
Reel/Frame 035695/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2015
From: KUNZLER, JAY FRIEDRICH; JANI, DHARMENDRA M.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 035695/0266 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2014
From: BAUSCH & LOMB INCORPORATED
To: UNIVERSITY OF ROCHESTER
Reel/Frame 033538/0812 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →